Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer
(MedPage Today) -- CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in certain patients with locally advanced head and neck squamous cell carcinoma (HNSCC), according...